TScan Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Tscan Therapeutics

12/08/2026 13:50

TScan Therapeutics Inc TCRX.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -28 cents.  The mean expectation of five analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -23 cents to -20 cents per share.
Revenue fell 65.8% to $1.05 million from a year ago; analysts expected $1.67 million. 
TScan Therapeutics Inc's reported EPS for the quarter was a loss of 23 cents​.
The company reported a quarterly loss of $30.36 million.
TScan Therapeutics Inc shares had fallen by 20.7% this quarter and lost 22.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 87.1% above its last closing price of $0.78
This summary was machine generated from LSEG data August 12 at 12:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.21
-0.23
Missed
Mar. 31 2026 
-0.17
-0.22
Missed
Dec. 31 2025 
-0.24
-0.18
Beat
Sep. 30 2025 
-0.30
-0.28
Beat